Detail Information

Publications41

Hossein JadvarDepartment of Radiology, Keck School of Medicine of USC, University of Southern California, Los Angeles, CaliforniaTheranostics 2:331-2. 2012

..The current evidence suggests that choline PET(/CT), particularly the 18F- label, may become routinely available, initially in many European countries, for the clinical imaging evaluation of men with prostate cancer...

..Our initial preclinical observations suggest that there may be an association between androgen signaling and thymidine metabolism and that (18)F-FMAU PET may be useful in prostate tumor characterization...

Prospective evaluation of 18F-NaF and 18F-FDG PET/CT in detection of occult metastatic disease in biochemical recurrence of prostate cancer

..Evidence from animal-based translational and human-based clinical studies points to a potential and emerging role for PET, using F-fluorodeoxyglucose as a radiotracer, in the imaging evaluation of prostate cancer...

..In this article, I review the preclinical and clinical evidence on the potential and emerging role of PET with the 3 most commonly studied radiotracers in prostate cancer, namely 18F-FDG, 18F- or 11C-acetate, and 18F- or 11C-choline...

Colonic FDG uptake pattern in subjects receiving oral contrast with no known or suspected colonic disease

..PET underestimated the extent of osseous metastatic disease in the remaining 4 patients. FDG PET is limited in the detection of osseous metastatic lesions but may be useful in the detection of metastatic nodal and soft tissue disease...

..Our results support the notions that FDG PET may be useful in the imaging evaluation of response to androgen ablation therapy and in the early prediction of hormone refractoriness in men with metastatic prostate cancer...

..We then review the preclinical and clinical evidence on the potential and emerging role of positron emission tomography with various radiotracers in the imaging evaluation of men with prostate cancer...

Risk stratification and stage migration effect of novel imaging and biomarker technology in men with biochemical failure after local therapy for prostate cancer

..0 (CTLD ≥10 mm) and RECIST 1.1 (CTSD ≥15mm), were calculated for both groups of pts. The response of concordant target LNs was assessed as CR, PR, SD and PD based on RECIST 1.0 and 1.1 cut-off points...